The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments 2021-2026

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• What's New in this Update
• Information Sources
• Methodology
• Analyst's Credentials
• Custom Research
• Related Reports

Chapter 2 Summary and Highlights

• Detection
• Handheld Devices
• Factors Contributing to the Market for Biodefense-Related Pathogen Identification
• Highlights of the U.S. Market for Biodefense-Related Rapid Pathogen Identification
• Treatment

Chapter 3 Industry Overview

• Introduction
• Delivery and Detection
• Methods of Dissemination
• Potential Biological Pathogens
• Rapid Identification Products
• Sensing Technology
• Detect-To-Warn Systems
• Treatment
• Vaccines
• Pharmaceuticals Used to Treat Biodefense-Related Pathogens
• Planning and Response to Bioterrorism Event
• Microbial Forensics
• Role of Government, Universities and Private Funding in Product Development
• Funding Options

Chapter 4 Overview of Infectious Agents

• Introduction
• Categories of Bacterial Agents
• Category a Bacterial Agents
• Category a Viral Agents
• Category B Bacterial Agents
• Category B Toxins

Chapter 5 Biodefense-Related Pathogen Detection Devices

• Pathogen Id Devices by Testing Method
• Types of Devices
• Diagnostic Tools
• Mass Spectrometry
• Pcr
• Immunological Analysis
• Biological Sensors
• Biodefense Biosensor Market

Chapter 6 Patents and Market Dynamics

• Introduction
• Patents on Rapid Pathogen Identification: 2019-2021
• Pharmaceutical Market Opportunities/Challenges
• Vaccine Market Opportunities/Challenges
• Device Market Opportunities/Challenges
• Challenges
• Opportunities

Chapter 7 Company Profiles

• Diagnostic Products
• Anp Technologies
• Alpha Diagnostic International
• Battelle
• Biomerieux Inc.
• Biosearch Technologies
• Biotech International
• Bruker Detection
• Corgenix Medical Corp.
• Diatherix
• Electronic Sensor Technology Inc.
• Haztech Systems
• Inbios International Inc.
• Integrated Nano-Technologies
• Menon Biosensors Inc.
• Meso Scale Defense
• Nanologix
• New Horizon Diagnostic Corp.
• Positive Id Corp.
• Thermo Fisher Scientific Inc.
• Vaccines
• Bavarian Nordic A/S
• Crucell Holland B.V.
• Emergent Biosolutions
• Inovio Pharmceuticals
• Novavax
• Pharmathene Inc.
• Soligenix
• Tapimmune
• Pharmaceuticals
• GlaxoSmithKline
• Merck
• Sarepta Therapeutics
• Siga Technologies
• National Laboratories
• Lawrence Livermore National Laboratories
• Sabin Vaccine Institute

Chapter 8 Appendix: List of Acronyms

List of Tables
Summary Table: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatment, by Type, Through 2026
Table 1: Class A: Bioterrorism Agents
Table 2: Class A: Pathogen Identification, by Transmission Method
Table 3: Class B: Bioterrorism Agents/Diseases
Table 4: Class B: Pathogen Identification, by Transmission Method
Table 5: Class C: Bioterrorism Agents/Diseases
Table 6: Additional Emerging Infectious Disease Pathogens
Table 7: Class C: Pathogen Identification, by Transmission Method
Table 8: Limitations of Some Common Analysis Methods
Table 9: Characteristics of Biosensors
Table 10: Detect-To-Warn Monitoring Systems
Table 11: Pathogen Vaccines, 2019
Table 12: Pharmaceuticals Used to Treat Biodefense-Related Pathogens, 2019
Table 13: Industrial R&D Expenditures in Life Science Technologies, 2017-2019
Table 14: Biodefense-Related Pathogen Identification with Test and Test Result Time
Table 15: Rapid Tests Used to Detect Anthrax <I>B. Anthracis Bacteria</I>
Table 16: Rapid Tests Used to Detect <I>Yersinia Pestis</I> Bacteria
Table 17: Rapid Tests Used to Detect <I>Francisella Tularensis</I> Bacteria
Table 18: Rapid Tests Used to Detect Smallpox
Table 19: Rapid Tests Used to Detect Pandemic Influenza
Table 20: Distribution of COVID-19 Clinical Symptoms
Table 21: Rapid Tests Used to Detect COVID-19
Table 22: Rapid Tests Used to Detect Ebola Hemorrhagic Fever
Table 23: Vaccines in Clinical Trials for Ebola Hemorrhagic Fever
Table 24: Pharmaceuticals in Clinical Trials for Ebola Hemorrhagic Fever
Table 25: Rapid Test to Detect Marburg Hemorrhagic Fever
Table 26: Rapid Tests Used to Detect Brucella
Table 27: Rapid Tests Used to Detect Salmonella
Table 28: Rapid Tests Used to Detect <I>E. Coli</I> Bacteria
Table 29: Rapid Tests Used to Detect <I>Burkholderia Mallei</I> Bacteria
Table 30: Rapid Test Used to Detect <I>Burkholderia Pseudomallei</I> Bacteria
Table 31: Rapid Tests Used to Detect <I>Chlamydia Psittaci</I> Bacteria
Table 32: Rapid Tests Used to Detect <I>Coxiella Burnetiid</I> Bacteria
Table 33: Rapid Tests Used to Detect Staphylococcal Enterotoxin B
Table 34: Method to Detect Salmonella <I>Typhi </I>Bacteria
Table 35: Vaccines Used to Prevent Typhoid Infections
Table 36: Rapid Tests Used to Detect <I>Vibro Cholerae</I> Bacteria
Table 37: Methods Used to Detect Cryptosporidium
Table 38: Rapid Tests Used to Detect Viral Encephalitis
Table 39: Rapid Tests to Diagnose Ricin Poisoning
Table 40: Rapid Tests Used to Detect Botulism Poisoning
Table 41: Vaccines to Treat Botulism
Table 42: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatment, by Type, Through 2026
Table 43: U.S. Market for Biodefense-Related Detection Devices, by Testing Method, Through 2026
Table 44: U.S. Market for Biodefense-Related Detection Devices, by Device Type, Through 2026
Table 45: U.S. Market for Biodefense-Related Mass Spectrometry Devices, Through 2026
Table 46: U.S. Market for Biodefense-Related Pcr Devices, Through 2026
Table 47: U.S. Market for Biodefense-Related Pcr Devices, by Technology, Through 2026
Table 48: U.S. Market for Biodefense-Related Immunological Devices, Through 2026
Table 49: U.S. Market for Biodefense-Related Biological Sensors, Through 2026
Table 50: U.S. Patents on Rapid Pathogen Identification Technologies, 2019-2021
Table 51: Anp Technologies: Diagnostic Products
Table 52: Alpha Diagnostic International: Diagnostic Products
Table 53: Battelle: Diagnostic Products
Table 54: Biomerieux: Biodefense-Related Diagnostic Products
Table 55: Biosearch Technologies: Diagnostic Products
Table 56: Biotech International: Biodefense-Related Diagnostic Product
Table 57: Bruker: Biodefense-Related Diagnostic Products
Table 58: Corgenix: Diagnostic Products
Table 59: Diatherix: Diagnostic Products
Table 60: Electronic Sensor Technology: Diagnostic Products
Table 61: Haztech: Biodefense-Related Products
Table 62: Inbios: Diagnostics Products
Table 63: Integrated Nano-Technologies: Diagnostics Products
Table 64: Menon Biosensors: Diagnostic Products
Table 65: Meso Scale Defense: Diagnostics Products
Table 66: Nanologix: Diagnostics Products
Table 67: New Horizon: Diagnostics Products
Table 68: Positive Id: Diagnostics Products
Table 69: Thermo Fisher Scientific: Products and Services
Table 70: Bavarian Nordic: Biodefense Vaccine Products
Table 71: Emergent Biosolutions: Vaccine Products
Table 72: Inovio Pharmaceuticals: Vaccine Products
Table 73: Novavax: Vaccine Products
Table 74: Pharmathene: Vaccine Products
Table 75: GlaxoSmithKline: Pharmaceutical Products
Table 76: Merck: Biodefense-Related Pharmaceutical Products
Table 77: Siga: Biodefense-Related Product
Table 78: Acronyms Used in the U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatment

List of Figures
Summary Figure: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatment, by Type, 2019-2026
Figure 1: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatment
Figure 2: U.S. Market Shares of Biodefense-Related Rapid Pathogen Detection Devices, by Testing Method, 2020 and 2026
Figure 3: U.S. Market Shares of Biodefense-Related Rapid Pathogen Detection Devices, by Device Type, 2020 and 2026
Figure 4: Thermo Fisher Scientific: Annual Revenue, 2018-2020
Figure 5: Thermo Fisher Scientific: Revenue Share, by Product Category, 2020

Executive Summary

Despite the renewal of the 1975 Biological Weapons Commission in 2009, the U.S. Department of State estimates that more than a dozen countries are developing biological weapons. Of significant concern is the possibility that domestic or international terrorist groups could acquire or create biological weapons and use them against unprotected civilian or military targets. The anthrax letter attacks in 2001, which resulted in the infection of 23 Americans and the death of five, heightened Americans’ sense of vulnerability. Since 2001, the U.S. government has spent or allocated more than $60 billion toward biological weapons research, which has included developing and distributing air sensors, educating doctors about the symptoms of bioterror pathogens and distributing medical supplies for biodefense to hospitals.

Biological substances that can be weaponized for either civilian or military destruction are a biodefense-related issue. Identifying these substances accurately and rapidly is at the heart of this report. Additionally, treatment methods such as vaccines and oral pharmaceuticals will be discussed.

Detection

Pathogenic agents can be viruses, bacteria, fungi, protozoa, parasites, or manufactured toxins. They can cause diseases in plants, animals and humans. Pathogens that are harmful to animals and plants are not covered in this report unless they pose an imminent danger, as did brucellosis or the plague, to humans through consumption. The infectious agents discussed in this report include smallpox, anthrax, plague and tularemia. Another area of pathogen identification includes potentially harmful chemical toxins that are used in biological warfare situations, such as ricin and botulinum.

Within the military and civilian arenas, the report covers products and strategies that identify pathogens introduced in the air, water and by other means. The report also reviews global metrics for known diseases, and it forecasts trends and indicators for the potential weaponization of these diseases. The process of rapid identification of potentially harmful pathogens falls into two categories: specimen testing (e.g., immunoassay) and sensors (e.g., airborne pathogens). Both identification methods are discussed in this report, and potential markets for products are projected through 2026.

The most frequently available detection tests are those aimed at detecting anthrax, smallpox, and tularemia. Some assays can detect more than one pathogen simultaneously. The most common combination tests include anthrax, smallpox, plague, tularemia, botulism and Staphylococcal enterotoxin B (SEB). The development of viral tests for pandemic influenza and COVID-19 is ongoing, but as with treatment, the detection of viruses is more complicated than that of bacterial pathogens.

Companies Mentioned

• Alpha Diagnostic International
• ANP Technologies
• Battelle
• Bavarian Nordic A/S
• Biomerieux Inc.
• Biosearch Technologies
• Biotech International
• Bruker Detection
• Corgenix Medical Corp.
• Crucell Holland B.V.
• Diatherix
• Electronic Sensor Technology Inc.
• Emergent Biosolutions
• GlaxoSmithKline
• Haztech Systems
• Inbios International Inc.
• Inovio Pharmceuticals
• Integrated Nano-Technologies
• Lawrence Livermore National Laboratories
• Menon Biosensors Inc.
• Merck
• Meso Scale Defense
• Nanologix
• National Laboratories
• New Horizon Diagnostic Corp.
• Novavax
• Pharmathene Inc.
• Positive ID Corp.
• Sabin Vaccine Institute
• Sarepta Therapeutics
• Siga Technologies
• Soligenix
• Tapimmune
• Thermo Fisher Scientific Inc.